Sign Up to like & get
recommendations!
1
Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10040862
Abstract: Despite poor response rates and dose-limiting cardiotoxicity, doxorubicin (doxo) remains the standard-of-care for patients with advanced soft tissue sarcoma. We evaluated the efficacy of two tetrapeptidic doxo prodrugs (PhAc-ALGP-Dox or CBR-049 and CBR-050) that are…
read more here.
Keywords:
thop1;
cbr 049;
soft tissue;
tissue sarcoma ... See more keywords